May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa tunnels have different microenvironments, suggesting targeted treatments could be more effective.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa tunnels have different microenvironments, suggesting targeted treatments could be more effective.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa tunnels have different microenvironments, suggesting targeted treatments could be more effective.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa tunnels have different microenvironments, suggesting targeted treatments could be more effective.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa is a chronic skin disorder linked to genetics, lifestyle, and immune issues, treatable with medications and surgery.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa is a chronic skin disorder linked to genetics, lifestyle, and immune issues, treatable with medication and sometimes surgery.
Blocking CXCR4 may help treat hidradenitis suppurativa.
July 2025 in “Journal of Investigative Dermatology” Reduced AhR signaling in HS tunnels leads to persistent inflammation and microbial imbalance.
January 2025 in “Excellence in Pediatrics Abstracts” Early recognition and treatment of hidradenitis suppurativa in children are crucial to prevent complications.
December 2024 in “JEADV Clinical Practice” COVID-19 vaccination is generally safe for people with Hidradenitis Suppurativa.
November 2024 in “Journal of Investigative Dermatology” Secukinumab reduces immune activity in hidradenitis suppurativa skin.
September 2024 in “Dokumentenrepositorium der RUB (Ruhr University Bochum)” Higher monocyte counts predict less effective adalimumab treatment in hidradenitis suppurativa patients.
September 2024 in “Journal of the American Academy of Dermatology” PRO-C22 can help diagnose and monitor the severity of hidradenitis suppurativa.
July 2024 in “Journal of Investigative Dermatology” Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.
May 2024 in “Lithuanian University of Health Sciences” Many patients with hidradenitis suppurativa also have severe acne and pilonidal cysts, often linked to other health problems.
January 2024 in “Advances in Dermatology and Allergology” New treatments offer hope for better managing hidradenitis suppurativa.
December 2023 in “Acta dermato-venereologica” Metformin might help treat certain skin conditions, but more research is needed.
December 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Early diagnosis and treatment of Folliculitis decalvans are crucial, especially in younger patients and those with bacterial infections.
November 2023 in “JAAD case reports” Exogenous testosterone use may be linked to developing hidradenitis suppurativa.
September 2023 in “Acta dermato-venereologica” Pilonidal sinus disease is linked to more severe hidradenitis suppurativa.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Skin organoids with NCSTN mutation show changes in hair follicle development and higher inflammation, key features of Hidradenitis Suppurativa.
October 2022 in “Dermatology practical & conceptual” People with hidradenitis suppurativa are more likely to have bipolar disorder than those with psoriasis or without skin conditions.
August 2022 in “JAAD case reports” A woman with a long-term skin condition developed a serious skin cancer that led to her death.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Targeting impaired Nrf2 signaling might help treat hidradenitis suppurativa early on.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
December 2020 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Hidradenitis suppurativa may be a type of autoinflammatory skin disease linked to gene mutations and immune system issues.
November 2020 in “Journal of the American Academy of Dermatology” Intense pulsed light with radiofrequency showed mixed results in improving quality of life for hidradenitis suppurativa patients, with no clinical improvements.